Sensus Healthcare Details Abstract on Keloid Treatment with SRT at the 2017 American Society for Dermatologic Surgery Annual Meeting

Press Release

BOCA RATON, Fla. (October 9, 2017) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announced today that an abstract was presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place on Oct. 5-8 in Chicago, illustrating the low recurrence rate of keloids post-keloidectomy with a biological effective dose 30 (BED 30) of SRT.

Recurrences of keloids are notorious in that approximately 71 percent of cases recur following a keloid excision alone. In comparison, the abstract reports a significantly lower keloid recurrence rate – less than 2 percent – when combining keloidectomy and excision site treatment with SRT (BED 30).

“This important abstract details the advantages of SRT for the treatment and prevention of keloids,” said Joe Sardano, President and CEO of Sensus Healthcare. “Due to how difficult they are to treat and their high rate of recurrence, Keloids can become a major affliction, significantly impacting a patients’ quality of life on a daily basis. The findings of this abstract highlight the fact that SRT is a safe and extremely effective supplement in treating existing keloid conditions and reducing the recurrence rate when combined with excision surgery.”

Authored by Dr. Brian Berman, M.D., Ph.D., and presented at ASDS by Dr. Mark Nestor, M.D., Ph.D., the abstract, entitled, “Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biological Effective Dose 30 of Superficial Radiation,” will also be presented at the upcoming Fall Clinical Dermatology Conference on Oct. 12-15, 2017, at The Wynn in Las Vegas.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.

About American Society for Dermatologic Surgery

American Society for Dermatologic Surgery (ASDS) is the largest specialty organization exclusively representing dermatologic surgeons who have unique training and experience to treat the health, function and beauty of your skin. ASDS members are pioneers in the field. Many are involved in the clinical studies that bring popular treatments to revitalize skin and fill and diminish wrinkles to the forefront. Their work has helped create and enhance many of the devices that remove blemishes, hair and fat, and tighten skin. Dermatologic surgeons also are experts in skin cancer prevention, detection and treatment. As the incidence of skin cancer rises, dermatologic surgeons are committed to taking steps to minimize the life-threatening effects of this disease. For more information, visit asds.net.

Media Contacts:
Caitlin Kasunich / Nick Opich
KCSA Strategic Communication
212-896-1241 / 212-896-1206
ckasunich@kcsa.com / nopich@ksca.com
 
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com

Share:
Share on FacebookTweet about this on TwitterShare on LinkedInEmail this to someone